智飞生物: 关于发行公司债券预案的公告

Core Viewpoint - Chongqing Zhifei Biological Products Co., Ltd. plans to issue corporate bonds to raise funds for technological innovation, debt restructuring, and working capital needs, with a total issuance scale not exceeding RMB 6 billion [1][2]. Group 1: Issuance Overview - The proposed bond issuance scale is up to RMB 60 billion, with the specific amount to be determined based on the company's funding needs and market conditions [2]. - The bonds will be issued through a book-building method, which may involve either a single issuance or multiple issuances [2]. - The face value of the bonds will be RMB 100, issued at par [2]. - The bonds will be offered to qualified professional investors, without preferential allocation to existing shareholders [2]. - The issuance will occur at an opportune time based on actual funding needs, on the Shenzhen Stock Exchange [2]. - The bond term will not exceed 10 years, including both public and private placements [2]. Group 2: Fund Utilization and Terms - The funds raised will be used for investments in technological innovation, debt replacement, and working capital, with specific allocations to be determined by the board [2][3]. - The bonds will have a fixed interest rate, determined through a pricing inquiry process, with interest paid annually and principal repaid at maturity [3]. - The bonds will be issued without collateral [4]. - The underwriting will be conducted through a firm commitment basis, with plans for listing on the Shenzhen Stock Exchange post-issuance [4]. Group 3: Authorization and Approval Process - The board seeks authorization from the shareholders' meeting to manage all aspects of the bond issuance, including terms and conditions [5][6]. - The issuance has been approved by the board and supervisory committee but requires shareholder approval and regulatory clearance before proceeding [6].